NEW: We have just launched DHbriefs to offer a series of research briefs covering specific digital health market niches. Click here for more information.

Shimmer’s Verisense wearable sensor aims to improve data quality in clinical trials

The Verisense platform provides complete clinical trial sponsor support, requiring a five-minute setup to initiate data collection and participant follow up.

Verisense-Shimmer.jpg

Shimmer’s Verisense wearable sensor aims to improve data quality in clinical trials

Wearable tech company Shimmer unveiled Verisense, its next-generation wearable sensor platform designed from the ground up to meet the needs of clinical trial sponsors, sites and participants.

“There is a growing demand from pharmaceutical companies, regulators and payers to factor real-world data (RWD) into healthcare decision making. They want to ensure that new therapies, especially those for chronic conditions, deliver objective improvements to participants’ health and quality of life,” Geoff Gill, president of Shimmer Americas, said in a statement. “That requires access to real-world participant data and has spurred the rapid growth in wearable technologies to measure objective quality of life indicators, such as activity levels and sleep patterns.”

Verisense is a comprehensive and flexible solution for reliably capturing accurate and complete biometric data. It is launching with the Verisense IMU sensor, a general-purpose Inertial Measurement Unit (IMU) that is worn on the wrist to monitor activity and sleep. In addition, it can be used for any IMU application with up to seven sensors worn on different parts of a participant’s body, making it invaluable for studying complex musculoskeletal or neurological conditions, such as dystonia or epilepsy. Furthermore, researchers can draw on a wealth of published data and established metrics from more than a decade of research using Shimmer devices.

“The new Verisense platform will allow me to build upon that experience using a device that was specifically developed for remote monitoring, providing access to raw data, offering quick system setup, a robust and secure data flow, and a six-month battery life which will be a boon for patient compliance and improved data quality,” commented Paolo Bonato, PhD, director of the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital in Boston, MA. Dr. Bonato is also an associate professor in the Department of Physical Medicine and Rehabilitation at Harvard Medical School, and an associate faculty member at the Wyss Institute for Biologically Inspired Engineering, Harvard University.

The Verisense platform provides complete clinical trial sponsor support, requiring just a five-minute setup to initiate data collection and participant follow up if the system alerts them to a critical issue. Sponsors gain access to all the raw participant data; they are uploaded to a secure site and can be transferred to an electronic data capture system automatically to ensure data integrity. Built-in algorithms provide validated metrics. A monitoring dashboard shows the status of all the sites at a glance, and provides the ability to drill down to every sensor in the study.

The Verisense platform places the minimum burden on participants. After putting the base station near their bed, or in another location that they visit every day, all they need to do is wear the sensor. It can even be worn in the shower or bath. The Verisense battery lasts for up to six months and the data transfer is completely automatic. The Verisense sensor can be inserted into a wide variety of cradles, ensuring that it meets all style and functional requirements.

Links: Source

Leave a Reply

NEW: DHbriefs offers series of research briefs covering specific digital health market niches. Click here for more information.
Top